HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
ABCL
AbCellera Biologics Inc
Healthcare Biotechnology · British Columbia, Canada · Reports in usd
Market Cap: $1.50B
Market Cap
$1.50B
Enterprise Val
$1.11B
P/E Ratio
-10.42
P/B Ratio
1.60
Trailing PEG (1Y)
1.56
As Of
May 11, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$938.1M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-14.86%
Return on Assets-10.62%
Current Ratio14.05
Debt/Equity0.14
LT Debt/Equity0.14
Revenue Per Share0.03

Income Statement

Mar 31, 2026
Revenue$8.3M
Cost of Revenue$0.00
Gross Profit$8.3M
R&D$46.7M
SG&A$12.3M
Operating Expenses$65.8M
Operating Income-$57.5M
Interest Expense-$3.6M
Tax Expense-$6.4M
Net Income-$43.2M
EPS (Basic)$-0.14
EPS (Diluted)$-0.14
EBIT-$53.2M
EBITDA-$44.5M
Consolidated Income-$43.2M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$102.1M
Accounts Receivable$36.8M
Inventory$0.00
Current Assets$664.6M
LT Investments$65.3M
Property, Plant & Equipment$422.8M
Intangibles$85.3M
Non-Current Assets$642.5M
Total Assets$1.31B
Accounts Payable$39.6M
Current Debt$0.00
Current Liabilities$47.3M
LT Debt$134.3M
Non-Current Liabilities$321.7M
Total Liabilities$369.0M
Total Debt$134.3M
Retained Earnings-$72.6M
Shareholder Equity$938.1M
Shares Outstanding303,160,487

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$33.5M
Investing Cash Flow-$25.1M
Financing Cash Flow$7.2M
CapEx-$3.8M
Free Cash Flow-$37.4M
Depreciation & Amort.$8.7M
Stock-Based Comp$12.0M
Acquisitions / Disposals$0.00
Investment Activity-$22.6M
Debt Issued/Repaid$7.2M
Equity Issued/Repaid$0.00
Dividends Paid$0.00
Net Change in Cash-$51.5M
Data cached · Meta live · Daily live · Statements live · TTL 24h